HEMATOLOGY

>

Latest News

Acalabrutinib Receives FDA Priority Review in Frontline MCL
Acalabrutinib Receives FDA Priority Review in Frontline MCL

October 3rd 2024

Acalabrutinib, a BTK inhibitor, has shown promising results in treating mantle cell lymphoma, with the FDA granting it priority review.

Lunning Evaluates CAR T-Cell Therapy for ASCT-Eligible and Ineligible DLBCL
Lunning Evaluates CAR T-Cell Therapy for ASCT-Eligible and Ineligible DLBCL

September 22nd 2024

FDA Clears Investigational New Drug Application for CD-001 in Oncology
FDA Clears Investigational New Drug Application for CD-001 in Oncology

September 20th 2024

Phase 2 REMARK Trial of RVU120 Doses First Patient With Lower-Risk MDS
Phase 2 REMARK Trial of RVU120 Doses First Patient With Lower-Risk MDS

September 19th 2024

From ABVD to Nivolumab-AVD: New Treatment Strategies in Hodgkin Lymphoma
From ABVD to Nivolumab-AVD: New Treatment Strategies in Hodgkin Lymphoma

September 18th 2024

Latest CME Events & Activities

6th Annual Precision Medicine Symposium: An Illustrated Tumor Board

October 18-19, 2024

Register Now!

Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

<1
...
8586878889